Utilization trend of prebiopsy multiparametric magnetic resonance imaging and its impact on prostate cancer detection: Real‐world insights from a high‐volume center in southwest China

Author:

Zhang Chichen1,Tu Xiang1,Dai Jindong1,Zhang Zilong1,Shen Chenlan2,Wu Qiyou1,Liu Zhenhua1,Lin Tianhai1,Qiu Shi13ORCID,Yang Lu1ORCID,Yang Ling4,Zhang Mengni5,Cai Diming6,Bao Yige1,Zeng Hao1,Wei Qiang1ORCID

Affiliation:

1. Department of Urology, Institute of Urology, West China Hospital Sichuan University Chengdu China

2. Department of Laboratory Medicine, Med+X Center for Manufacturing, West China Hospital Sichuan University Chengdu China

3. Department of Molecular Oncology, Institute of Oncology Research (IOR) Oncology Institute of Southern Switzerland (IOSI) Bellinzona Switzerland

4. Department of Radiology, West China Hospital Sichuan University Chengdu China

5. Department of Pathology and Laboratory of Pathology, State Key Laboratory of Biotherapy, West China Hospital, West China Medical School Sichuan University Chengdu China

6. Department of Ultrasound, West China Hospital Sichuan University Chengdu China

Abstract

AbstractBackgroundData on the utilization and effects of prebiopsy prostate multiparametric magnetic resonance imaging (mpMRI) to support its routine use in real‐world setting are still scarce.ObjectiveTo evaluate the change of clinical practice of prebiopsy mpMRI over time, and assess its diagnostic accuracy.Design, Setting, and ParticipantsWe retrospectively analyzed data from 6168 patients who underwent primary prostate biopsy (PBx) between January 2011 and December 2021 and had prostate‐specific antigen (PSA) values ranging from 3 to 100 ng/mL.InterventionPrebiopsy MRI at the time of PBx.Outcome Measurements and Statistical AnalysisWe performed general linear regression and to elucidate trends in the annual use of prebiopsy mpMRI and conducted multivariable logistic regression to evaluate the potential benefits of incorporating prebiopsy mpMRI for prostate cancer (PCa) detection.Results and LimitationsThe utilization of prebiopsy mpMRI significantly increased from 9.2% in 2011 to 75.0% in 2021 (p < 0.001). In addition, prebiopsy mpMRI significantly reduced negative PBx by 8.6% while improving the detection of clinically significant PCa (csPCa) by 7.0%. Regression analysis showed that the utilization of prebiopsy mpMRI was significantly associated with a 48% (95% confidence interval [CI]: 1.19–1.84) and 36% (95% CI: 1.12–1.66) increased PCa detection rate in the PSA 3–10 ng/mL and 10–20 ng/mL groups, respectively; and a 34% increased csPCa detection rate in the PSA 10–20 ng/mL group (95% CI: 1.09–1.64). The retrospective design and the single center cohort constituted the limitations of this study.ConclusionsOur study demonstrated a notable rise in the utilization of prebiopsy mpMRI in the past decade. The adoption of this imaging technique was significantly associated with an increased probability of detecting prostate cancer.Patient SummaryFrom 2011 to 2021, we demonstrated a steady increase in the utilization of prebiopsy mpMRI among biopsy‐naïve men. We also confirmed the positive impact of prebiopsy mpMRI utilization on the detection of prostate cancer.

Publisher

Wiley

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3